Table 1.

Effect of GnRH blockers on histamine release

Compound (µg ml−1)	Mean basal histamine release (pmol g−1± SEM)	n	Effect (% increase ± SEM)	Compound 48/80 (% increase ± SEM)	Histamine liberating trend occurs at
Degarelix					>30 µg ml−1
Control	229 ± 17	8	9 ± 6	476 ± 161*
3	252 ± 19	8	–2 ± 5	283 ± 46*
30	241 ± 19	8	3 ± 5	209 ± 37*
300	183 ± 18	8	27 ± 6	234 ± 55*
Placebo	282 ± 51	8	0 ± 4	416 ± 144*
Ganirelix					>10 µg ml−1
Control	328 ± 34	6	9 ± 6	166 ± 30*
1	333 ± 39	6	5 ± 10	269 ± 104*
10	328 ± 43	6	7 ± 6	272 ± 116*
100	312 ± 45	6	81 ± 27	231 ± 68*
Abarelix					<3 µg ml−1
Control	257 ± 38	6	–3 ± 3	325 ± 96
3	340 ± 47	6	56 ± 11	107 ± 18
30	362 ± 43*	6	143 ± 29	80 ± 19
300	350 ± 58*	6	362 ± 58	234 ± 36
Cetrorelix					<3 µg ml−1
Control	238 ± 47	6	–1 ± 2.0	299 ± 137
3	209 ± 26	6	67 ± 28	51 ± 29
30	198 ± 24*	6	228 ± 111	60 ± 27
300	227 ± 16*	6	279 ± 46	68 ± 21

^*P < 0.05 stimulated release/basal absolute release tested.